Factors Predicting Progression of Diabetic Retinopathy by Janani, Sreenivasan
Dissertation on 
 
FACTORS PREDICTING PROGRESSION OF DIABETIC 
RETINOPATHY 
 
Submitted in partial fulfillment of requirements of 
M.S. OPHTHALMOLOGY 
BRANCH - III 
 
 
REGIONAL INSTITUTE OF OPHTHALMOLOGY 
MADRAS MEDICAL COLLEGE 
CHENNAI- 600 003 
 
 
 
 
 
 
THE TAMILNADU 
DR.M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
 
APRIL 2016 
 
 
 
 CERTIFICATE 
 
 
This is to certify that this dissertation titled “FACTORS PREDICTING 
 
PROGRESSION OF DIABETIC RETINOPATHY” is a bonafide record of 
 
the research Work done by DR. JANANI SREENIVASAN, Post graduate in the 
 
Regional Institute of Ophthalmology & Government Ophthalmic Hospital, 
 
Madras Medical College and Government General Hospital, Chennai-03, in 
 
partial fulfillment of the regulations laid down by the Tamil Nadu Dr. M.G.R 
 
Medical University for the award of M.S. Ophthalmology Branch III, under my 
 
guidance and supervision during the academic year 2013 – 2016. 
 
 
 
 
 
 
PROF. DR. K SRIDHAR.M.S., D.O.,                       
CHIEF, VITREORETINA SERVICES,                                                                                     
Regional Institute of Ophthalmology & Government Ophthalmic Hospital,  
Madras Medical College, Chennai-600 008. 
 
 
 
 
 
PROF.DR.K.NAMITHA BHUVANESWARI M.S., D.O.,                                                                    
DIRECTOR AND SUPERINTENDENT, 
Regional Institute of Ophthalmology & Government Ophthalmic Hospital, 
Madras Medical College, Chennai-600 008. 
 
 
 
 
 
PROF. DR.R.VIMALA.M.D.,  
DEAN, 
Madras Medical College & Government General Hospital,  
Chennai-600 003. 
ACKNOWLEDGEMENT 
I express my sincere thanks and gratitude to PROF. DR. R. VIMALA, M.D., 
Dean, Madras Medical College and Government General Hospital, Chennai for 
permitting me to conduct this study at the Regional Institute of Ophthalmology and 
Government Ophthalmic Hospital, Chennai. 
I have great pleasure in thanking PROF.  DR. K. NAMITHA 
BHUVANESWARI  M.S.,  D.O.,  Director and Superintendent,  Regional Institute of 
Ophthalmology and Government Ophthalmic Hospital, Madras Medical College, for 
her valuable advice in preparing this dissertation. 
I express my profound gratitude to PROF. DR. K. SRIDHAR, M.S., D.O., my 
unit chief and my guide for his valuable guidance and constant support at every stage 
throughout the period of this study. 
I  am  very  grateful  to  my  Co-guides,  my  unit  chief, PROF. DR. B. 
CHANDRASEKARAN, M.S. D.O., and my unit assistant professor,  DR. M. 
PERIYANAYAGI, M.S.,  for rendering their valuable advice and guidance for this 
study. 
I  am  extremely  thankful  to  my  unit  assistant  professors, DR. M. SIVAKAMI. 
M. S., and DR. K. SIVAKUMAR, M.S., for their valuable suggestions and guidance 
during the course of this study. 
I wish to express my sincere thanks to all the professors, assistant professors and 
all my colleagues who had helped me in bringing out this study. Finally, I am indebted 
to all the patients for their sincere co-operation for the completion of this study. 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 DECLARATION BY THE CANDIDATE 
I hereby declare that this dissertation entitled “FACTORS PREDICTING 
PROGRESSION OF DIABETIC RETINOPATHY” is a bonafide and genuine 
research work carried out by me under the guidance of PROF. DR. K. 
SRIDHAR., M.S. D.O. 
 
 
 
DATE:  
PLACE:                                                                DR. JANANI SREENIVASAN 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CONTENTS 
S.NO. TITLE PAGE NO. 
PART I 
1. INTRODUCTION 1 
2. REVIEW OF LITERATURE 3 
A. HISTORY 5 
B. ANATOMY 6 
C. EPIDEMIOLOGY 8 
D. CLASSIFICATION 13 
E. PATHOGENESIS 17 
F. CLINICAL FEATURES 21 
G. CLINICAL EVALUATION 25 
H. MANAGEMENT 27 
I. ERG IN DIABETIC RETINOPATHY 31 
J. FACTORS PREDICTING PROGRESSION 
OF DIABETIC  RETINOPATHY 
36 
K. SCREENING SCHEDULE AND ETDRS 
RECOMMENDATIONS FOR FOLLOW UP 
40 
PART II 
3. AIMS AND OBJECTIVES 41 
4. MATERIALS AND METHODS 42 
5. OBSERVATION AND ANALYSIS 48 
6. DISCUSSION 77 
7. SUMMARY 87 
8. LIMITATIONS OF THE STUDY 90 
9.  CONCLUSION 91 
PART III 
10. BIBILIOGRAPHY 92 
11. PROFORMA 102 
12. KEY TO MASTER CHART 105 
13. MASTER CHART 106 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ABBREVIATIONS 
 
PDR – Proliferative diabetic retinopathy  
NPDR – Non proliferative diabetic retinopathy  
IDDM – Insulin dependent diabetes mellitus  
NIDDM – Non insulin dependent diabetes mellitus  
FBS – Fasting blood glucose  
PPBS – Post prandial blood glucose  
HT - Hypertension 
SBP – Systolic Blood Pressure 
DBP – Diastolic Blood Pressure 
CAD – Coronary artery Disease 
VEGF – Vascular endothelial growth factor  
NVD – New vessels on the disc  
NVE – New vessels elsewhere  
CSME – Clinically significant macular edema  
FFA – Fundus fluorescein angiography  
BCVA – Best corrected visual acuity  
OHA – Oral hypoglycemic agents  
IOP – Intraocular pressure 
PKC – Protein Kinase C 
OP – Oscillatory Potentials 
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INTRODUCTION 
 Diabetes Mellitus is a heterogeneous group of metabolic diseases 
characterized by hyperglycaemia resulting from defects in insulin secretion, 
insulin resistance, or both. Diabetes is gaining the status of a potential epidemic 
in India with more than 62 million individuals currently diagnosed with the 
disease (1). Diabetes Mellitus is known to cause macro vascular complications 
like cardiovascular disease, cerebrovascular disease and peripheral vascular 
disease & microvascular complications such as neuropathy, nephropathy, and 
retinopathy.  
Among the ophthalmic complications are corneal abnormalities, pupillary 
abnormalities, iris neovascularisation, glaucoma, cataracts and retinopathy. 
However the commonest ophthalmic complication remains diabetic retinopathy, 
a vision threatening disorder. Due to the increasing incidence of diabetes, the 
burden of blindness caused by diabetic retinopathy is on the rise. Hence newer 
modalities of diagnosis and treatment are also in evolution, with prime focus on 
early detection and halting the progression.  
Duration of diabetes is considered to be one of the most significant 
parameters in predicting both occurrence and progression of diabetic retinopathy 
(23).  
The Diabetes Control and Complications Trial (DCCT) demonstrated that 
intensive glycaemic control markedly reduces the risks of incidence or 
progression of retinopathy and other complications of type I DM, when compared 
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with a conventional treatment. Long-term control of hyperglycaemia is an 
important risk factor for the progression of diabetic retinopathy and that lower 
levels of HbA1c achieved even later in the course of diabetes, can modify the risk 
imposed by higher levels earlier in the course of disease (13). 
Hypertension aggravates the retinal ischemia caused by diabetic 
retinopathy. Both systolic and diastolic blood pressure contribute to retinal 
ischemia which is the central dogma for the retinopathy progression.  
The oscillatory potentials in electro retinogram can pick up inner retinal 
ischemia early and give the idea of which patients are more likely to progress so 
that these patients can be followed up closely and treated appropriately. Although 
diabetic retinopathy is considered as vascular disorder of the retina, recently it 
has been found that there is a neuro degenerative component primarily due to the 
disease itself or secondary to retinal ischemia (35). This observation has thrown 
light in to the fact that diabetic retinopathy can cause multiple abnormalities in 
electroretinogram.  
In this study, we measure Fasting blood sugar levels, Blood pressure and 
record oscillatory potentials in patients with moderate and severe NPDR and 
observe them for progression during the follow up.  
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REVIEW OF LITERATURE 
Diabetic retinopathy is one of the vision threatening microvascular 
complication that can occur in type I or type II diabetes mellitus. The causes of 
loss of vision in diabetic retinopathy could be macular edema, macular ischemia, 
vitreous hemorrhage, tractional retinal detachment and neovascular glaucoma. 
The Wisconsin epidemiologic study of diabetic retinopathy stated that 
progression of retinopathy was more likely associated with more severe 
retinopathy at baseline, male gender, having higher baseline glycosylated 
hemoglobin or high baseline diastolic blood pressure. Increased incidence of 
macular edema was associated with more severe baseline retinopathy, presence 
of hypertension and higher glycosylated hemoglobin at baseline, presence of 
gross proteinuria at baseline and an increase in the glycosylated hemoglobin 
between the baseline and follow-up examination (8).  
In “Tight blood pressure control and risk of macrovascular and 
microvascular complications in type 2 diabetes”, UK Prospective Diabetes Study 
Group, after a follow up period of nine years, tight blood pressure control group 
had a 34% reduction in risk in the proportion of patients with deterioration of 
retinopathy by two steps and a 47% reduced risk of deterioration in visual acuity 
by three lines of the early treatment of diabetic retinopathy study (ETDRS) chart 
(12). 
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In a study report by Bresnick GH et al, amplitudes of the oscillatory 
potential (OP) were measured in a group of 85 diabetic patients entering the Early 
Treatment Diabetic Retinopathy Study (ETDRS). The rate of progression to the 
Diabetic Retinopathy Study high-risk characteristics (DRS-HRC) during a ten- to 
40-month follow-up period was determined. Progression occurred in 19 of 85 
eyes at risk. Those eyes with abnormal OP amplitudes at baseline had a tenfold 
higher rate of progression to DRS-HRC than did eyes with normal amplitudes of 
OPs (33). 
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HISTORY 
Diabetic maculopathy was observed by Edward jaeger for the first time in 
1856. He noticed yellowish spots and extravasations that permeated partial or 
entire thickness of retina. On the contrary, Von Graefe said that there was no 
definitive proof of causal relationship between diabetes mellitus and retinal 
changes.  
      In 1872, the first histopathological proof of “Cystoid degeneration” of macula 
was given by Edward Nettleship in his paper on “Edema or cystic disease of 
retina”. Wilhelm Manz was the one who described the proliferative changes that 
occur in diabetic retinopathy. 
     The controversy continued till 1943, when the work of Arthur James 
Ballansync provided enough evidence for diabetic retinopathy representing a 
unique form of vascular disorder. 
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ANATOMY 
The retinal tissue is unique because it can be visualised, allowing the 
clinician to observe directly the effects of diseases such as an infarction  in 
evolution, deposition of metabolic storage products, or axoplasmic stasis. Retina 
extends from ora serrata anteriorly to optic disc posteriorly.  It consists of outer 
pigment epithelium and inner neurosensory retina (9 layers). Neurosensory retina 
is developed from inner layer of optic cup & RPE layer is developed from outer 
layer of optic cup, meaning both the layers are derivatives of neuroectoderm.  
Optic disc is a pale pink, well defined circular area of about 1.5 mm 
diameter. At the disc all the retinal layers terminate except the nerve fibres which 
pass through lamina cribrosa to run into optic nerve. The cup of the disc is a 
depression seen in it. Central retinal vessels emerge through the centre of the cup.  
Macula lutea is a comparatively dark area of 5.5 mm in diameter, situated 
at the posterior pole temporal to optic disc. It corresponds to approximately 15 
degree of visual field. Fovea centralis is the central depressed part of the macula 
of about 1.5mm (1DD) in diameter. It is the most sensitive part of retina. It 
corresponds to the 5 degree of visual field. Surrounding the fovea are 
circumferential zones, parafoveal & perifoveal areas measuring about 0.5mm & 
1.5mm respectively. Foveola forms the central floor of fovea which is around 
0.35 mm in diameter. It is the thinnest part of retina, consists of only densely 
packed cones & their nuclei. Umbo is a tiny depression in the centre of foveola 
which corresponds to the foveolar reflex (FR).  
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 Light microscopic histology of retina reveals the presence of ten layers 
namely (outside in): 1. Retinal pigment epithelium, 2. Layer of rods and cones,           
3. External limiting membrane, 4. Outer nuclear layer, 5. Outer plexiform layer,            
6. Inner nuclear layer, 7. Inner plexiform layer, 8. Ganglion cell layer, 9. Nerve 
fiber layer and 10. Internal Limiting Membrane. 
Blood Supply  
Outer four layers gets supply from choriocapillaries. Six inner layers get 
their supply from central retinal artery. Fovea is avascular but partially gets its 
blood supply from choriocapillaries. Macular region gets blood supply from twigs 
of superior or inferior branch of central retinal artery.  
Blood Retinal Barrier 
The outer BRB is formed by RPE. The inner BRB is formed by the 
capillary endothelial cells. The endothelial cells of retinal capillaries are closely 
bound together by intercellular tight junctions of the zona occludens type. These 
junctions normally prohibit a free flow of fluids & solutes from the lumen to the 
interstitium. Presence of BRB is confirmed by the absence of leak in FFA.  
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EPIDEMIOLOGY 
According to the 2004 WHO publication, there are 171 million people 
worldwide suffering from diabetes mellitus, a figure which is predicted to be 
doubled by 2030. In 2002, 5 million people were blind because of diabetic 
retinopathy, constituting around 5% of the world blindness.  
In India, The prevalence of diabetic retinopathy is found to vary between 
10.5% and 26.2%. It is one of the leading causes of new blindness in individuals 
between 20 to 74 years of age in both developed and developing countries. 
Because of this increasing incidence, it has been included in the "priority list" of 
"Vision 2020" (2).  
Type 1 diabetes mellitus (IDDM) comprises of 10-15% of all diabetic 
patients, type 2 diabetes mellitus (NIDDM) accounting for the remaining 85-
90%. In type 1 diabetes of duration less than 5 years, diabetic retinopathy is seen 
in 13% of patients, which dramatically increases to 90% with a duration of 10-15 
years and almost 100% with a duration of greater than 20 years. Even in NIDDM, 
there is an increased incidence of diabetic retinopathy with increasing duration of 
diabetes. While patients with Type 1 diabetes have a higher incidence of diabetic 
retinopathy, type 2 diabetes still accounts for majority of the cases observed, due 
to its increased prevalence.  
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In the WESDR, The prevalence of non-proliferative retinopathy, 
proliferative retinopathy and diabetic macular edema was reported to be 71%, 
23% and 11% in IDDM and 47%, 6% and 8% in NIDDM respectively. This study 
reported a 10 year incidence of retinopathy in IDDM below 30 years of age as 
89% and that above 30 years age as 79%. In Type II DM patients greater the 30 
years of age, the incidence of retinopathy is less in the estimates provided by more 
recent population-based studies (8). 
Due to advances in the screening, diagnosis and management of diabetes, 
the prevalence of diabetic retinopathy and its consequential visual loss has not 
been found to increase, accompanying the increased prevalence of diabetes 
epidemic which has been noted in the recent years. This is attributed to a stricter 
glycemic control in patients with IDDM.  
Following the UKPDS study there was an increase in the management of 
Type II diabetes using multiple oral hypoglycemic agents, as opposed to the use 
of only one such drug prior to this study. This resulted in a drop in the mean 
HbA1c levels from 7.8% to 7.2% and a 41% increase in patients attaining mean 
HbA1c levels of less than 7%. 
FACTORS INFLUENCING INCIDENCE OF DIABETIC RETINOPATHY  
1.  Duration of diabetes  
This is one of the most consistent risk factors for the development and 
progression of diabetic retinopathy (23). It is also a significant risk factor for the 
development of maculopathy. In Type I DM, retinopathy develops at least 3-4 
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years after disease onset. Since the duration of development in type 2 diabetes is 
difficult to determine, retinopathy may present as an early sign soon after 
diagnosis.  
2.  Age  
An increase in the prevalence of retinopathy has been noticed as age 
advances. The hormonal changes occurring during puberty influence the 
progression of retinopathy.  
3.  Sex incidence  
In the WESDR study, an increased incidence of proliferative diabetic 
retinopathy was observed in men with an earlier onset of diabetes than women 
but there was no significant difference in the prevalence or progression of 
retinopathy between males and females (8).  
4.  Race  
Blacks have a 20% higher incidence than whites. Several studies have 
shown that the prevalence of retinopathy in NIDDM was higher in African 
Americans. In studies like NHANES (1988-94 and 2005-8) and the MESA, 
retinopathy was more common in Mexican Americans then the non-Hispanic 
whites who were 40 years of age or older (48). 
5.  Genetic factors  
Data from several studies have revealed familial clustering of diabetic 
retinopathy suggesting a genetic susceptibility. Patients with HLA DR 4 and DR 
5 phenotype have been found to possess an increased risk of PDR. Individuals 
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with HLA B 15 are more likely to develop diabetic retinopathy, while individuals 
with HLA B 7 are 4 times less likely to develop PDR.  
6.  Glycemic status 
According to the Diabetic Control and Complications Trial (DCCT), a 10% 
reduction in HbA1c (from 8% to 7.2%) results in 35% to 40% reduction in 
incidence of diabetic retinopathy (13). The Wisconsin Epidemiologic Study of 
Diabetic Retinopathy (WESDR) demonstrated that the incidence of diabetic 
complications is directly related to glycemic control (8). The results of the 
Diabetes Control and Complications Trial, the U.K. Prospective Diabetes Study 
Group, the Kumamoto trial and Stockholm Study clearly showed that improved 
glycemic control decreased diabetic complications in people with type 1 diabetes 
(29). 
7.  Hypertension  
Increased systolic blood pressure levels increase the risk of incidence and 
progression of retinopathy. A similar association has been found between an 
increase in diastolic blood pressure and a rise in the incidence of diabetic macular 
edema. The UKPDS demonstrated on decreasing the systolic blood pressure, 
there was reduction in the incidence of microvascular complications of diabetes 
including retinopathy (12).  
 
 
 
12 
 
8.  Proteinuria and diabetic nephropathy  
Diabetic nephropathy has been found to be a significant risk factor in the 
development and progression of diabetic retinopathy. Diabetic macular edema is 
more common and more severe in patients with nephropathy (8). 
9.  Serum lipids  
In the ETDRS, increased levels of serum lipids at baseline were closely 
associated with high incidence of hard exudates at the macula, thereby reduced 
visual acuity (10). 
10.  Ocular factors  
Glaucoma, myopia and retino-choroidal scarring from trauma and 
inflammation have been proposed to protect against the development and 
progression of retinopathy.  
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CLASSIFICATION 
 The Airlie House standardized classification consisted of comparing 
stereo photographs in 7 standard fundus photographic fields with the patient’s 
findings in those same 7 photographic fields and classifies DR into 13 complex 
levels ranging from level 10 to level 85. Modified form of this classification was 
used in the Diabetic Retinopathy Study (DRS) and Early Treatment of Diabetic 
Retinopathy Study (ETDRS). The modified classification is as follows:  
NPDR (Non Proliferative Diabetic Retinopathy) 
Mild NPDR At least one microaneurysm and definition not met for moderate NPDR.  
Moderate 
NPDR 
· Severe retinal haemorrhages (more than ETDRS standard photograph 2A: 
about 20 medium-large per quadrant) in 1-3 quadrants or mild intraretinal 
microvascular abnormalities (IRMA).  
· Significant venous beading can be present in no more than 1 quadrant.  
· Cotton wool spots are commonly present.  
Severe 
NPDR 
The 4-2-1 rule; one or more of:  
· Severe haemorrhages in all 4 quadrants  
· Significant venous beading in 2 or more quadrants  
· Moderate IRMA in 1 or more quadrants  
Very severe 
NPDR 
Two or more of the criteria for severe NPDR. 
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 PROLIFERATIVE DIABETIC RETINOPATHY 
EARLY New vessels on the disc (NVD) or new 
vessels elsewhere (NVE), but extent 
insufficient to meet the high-risk criteria.  
HIGH RISK · New vessels on the disc (NVD) greater than 
ETDRS standard photograph 10A (about ½ 
disc area)  
· Any NVD with vitreous or preretinal 
haemorrhage  
· NVE greater than ½ disc area with vitreous 
or preretinal haemorrhage (or  haemorrhage  
with presumed obscured NVD/E) 
 
 
  
Clinically 
significant 
macular edema 
(CSME) 
· Retinal thickening within 500 microns of the centre of the macula  
· Exudates within 500 microns of the centre of the macula, if associated 
with retinal thickening (which may be outside the 500 microns)  
· Retinal thickening one disc area (1500 microns) or larger, any part of 
which is within one disc diameter of the centre of the macula. 
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PATHOGENESIS OF DIABETIC RETINOPATHY 
Chronic hyperglycemia is the major etiologic factor leading to all of the 
microvascular complications of diabetes like diabetic retinopathy. The 
mechanisms by which it leads to development of diabetic retinopathy can be 
classified as biochemical factors, rheological factors and anatomical changes.  
BIOCHEMICAL MECHANISMS: 
1. The Aldose reductase pathway: 
The aldose reductase pathway also called as sorbitol pathway is a series of 
intracellular reactions involving two enzymes utilizing NADPH, wherein aldose 
reductase reduces glucose to sorbitol which is then oxidized into fructose by 
sorbitol dehydrogenase. This pathway is highly activated in hyperglycemia. The 
sorbitol dehydrogenase step is slow, hence sorbitol may accumulate in high 
concentrations and the accumulated sorbitol does not easily permeate the plasma 
membranes. Thus polyol pathway leads to oxidative stress and depletion of 
NADPH inviting cellular damage.  
Advanced Glycation End Products (AGEs) Theory: 
Advanced glycation end products (AGEs) is the collective name given to 
proteins, lipids and nucleic acids that undergo irreversible modification by 
reducing sugars or sugar derived products. The series of chemical reactions that 
lead to formation of AGEs is called “MAILLARD REACTION”. HbA1c and 
fructosamine are examples of AGEs, used as clinical markers of diabetes. AGEs 
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can damage cells by impairing the function of variety of proteins including both 
extracellular and intracellular proteins. The cellular effect of AGEs is mediated 
by its binding to receptors namely Receptors for AGEs (RAGE).  
 
Reactive Oxygen Intermediates (ROI) Theory:  
The usual metabolic pathway of glucose is via glycolysis and tricarboxylic 
acid cycle which yields reducing equivalents used for synthesis of ATP via 
oxidative phosphorylation. The byproducts of these reactions includes free 
radicals like superoxide anion whose production is increased by hyperglycemia. 
The free radicals can damage mitochondrial DNA and cellular proteins.  
Protein kinase C pathway: 
  Elevated glucose levels result in increased de novo synthesis of 
Diacylglycerol (DAG) which activates protein kinase C through the activation of 
phospholipase C. PKC causes vascular damage by increasing vascular 
permeability, disruption of nitric oxide regulation, increased leukocyte adhesion 
to vessel wall and changes in blood flow.  
ANATOMIC LESIONS:    
I .Loss Of Pericytes: 
   Loss of pericytes is one of the earliest signs of diabetic retinopathy. Pericytes 
are contractile cells that play an important role in microvascular autoregulation. 
Loss of pericytes leads to impairment of inner blood retinal barrier. These effects 
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result in venous dilatation & tortuosity and endothelial proliferation forming 
microaneurysms.  
II. Capillary Basement Membrane Thickening: 
     Thickening of capillary basement membrane, deposition of fibrillar collagen, 
"Swiss cheese" vacuolization of the otherwise homogenous pattern of basement 
membrane collagen are the well documented electron microscopic findings in 
diabetic retinopathy.  
III. Capillary acellularity: 
      Complete loss of cellular elements of the retinal capillary network can be seen 
as a more advanced microvasular lesion in diabetic retinopathy. But this is a 
nonspecific finding. 
IV. Breakdown of blood retinal barrier: 
  Breakdown of B-R-B is an important pathophysiologic feature of diabetic 
retinopathy leading to the development of sight threatening macular edema. The 
tight junctions between vascular endothelial cells are called zona occludens (ZO). 
The two important proteins involved in the formation and function of zona 
occludens are ZO-1 and occludin. High glucose decreases the expression of ZO-
1. Vascular Endothelial Growth Factor (VEGF) and the mediators of Kallikrein-
kinin system both of which are upregulated in diabetes play important roles in 
breakdown of blood retinal barrier.  
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RHEOLOGICAL FACTORS: 
1.  Platelet abnormalities  
An increased platelet adhesiveness and aggregation and decreased platelet 
survival has been demonstrated by various studies.  
2.  Red blood cell abnormalities  
A decreased deformability and increased formation of rouleaux aggregates 
has been shown. A multitude of factors contribute to increased red cell 
aggregation such as increased level of fibrinogen and alpha 2 globulin, inhibition 
of plasmin by alpha 2 globulin and diminished fibrinolytic response. The 
increased erythrocyte aggregation results in increased blood viscosity and micro 
infarction of the retinal vasculature. 
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CLINICAL FEATURES 
Diabetic retinopathy can be broadly classified into the proliferative and 
non-proliferative categories. The hallmark of proliferative retinopathy being 
presence of new vessels in the retina and optic disc. The clinical features in 
general are discussed as follows:  
1.   Microaneurysms  
These are usually the first visible signs of diabetic reinopathy and the 
hallmark of NPDR. They are identified ophthalmoscopically as red dots, most 
commonly in the posterior pole. Their size ranges from 15 to 60 microns in 
diameter. Histologically, they are hypercellular outpouchings of the capillary 
wall. On FFA, they can be identified as punctate hyperfluorescent dots much 
more extensive than those identified clinically.  
2.   Hard exudates  
Hard exudates are yellowish-white deposits with distinct margins. They are 
formed of lipid laden macrophages due to lipid extravasation and are usually seen 
as discrete intra retinal deposits surrounding microaneurysms in a circinate ring. 
They are usually located in the outer plexiform layer. 
3.   Soft exudates 
These are small, whitish, fluffy, superficial lesions that represent infarction 
of the retinal nerve fiber layer with accumulation of neuronal debris. The swollen 
ends of the disrupted nerve axons are known as cystoid bodies. It’s a misnomer, 
not a true exudation. 
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4.   Intraretinal Microvascular Abnormalities(IRMA) 
These are arteriovenous shunts that run from retinal arterioles to venules, 
bypassing the capillary bed. Hence they are seen in areas adjacent to marked 
capillary non-perfusion as fine, red, irregular intraretinal lines. 
5.   Venous abnormalities-  
Venous changes observed include dilatation and tortuosity, sausage like 
segmentation, looping and beading consisting of focal narrowing and dilatation. 
These changes correlate with high risk of developing proliferative changes.  
6.   Arteriolar abnormalities-  
These are early markers of ischemic changes and include peripheral 
narrowing, silver-wiring and vascular obliteration.  
7.   Capillary closure  
It is one of the most important features of diabetic retinopathy, the extent 
and location of which is most accurately visualised on fluorescein angiography. 
8.   Retinal haemorrhages  
They may be superficial or deep and are seen predominantly on the 
posterior pole.  They may disappear only to reappear in a different area of the 
retina. Dot and blot haemorrhages are located within the compact deeper layers 
of the retina and result from venous engorgement of capillaries. Flame shaped 
haemorrhages arise in the nerve fibre layer from pre-capillary arterioles. 
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9.   Preretinal haemorrhage 
Both boat shaped haemorrhages with a fluid level and round, oval or linear 
patches of the haemorrhage just anterior to the retina or under its internal limiting 
membrane are included in pre-retinal haemorrhages. Haemorrhages on the 
surface of the detached retina, is also considered to be preretinal hemorrhage.  
10.   Diabetic macular edema 
Localized edema is caused by focal leakage from dilated capillary 
segments or microaneurysms, while diffuse retinal edema is caused by extensive 
capillary leakage. Lipid may also escape into the extravascular space and collect 
within the retina forming hard exudates. The fluid initially accumulates between 
the inner nuclear layer and the outer plexiform layer, however it may eventually 
involve the entire thickness of the retina.  
11.   New vessels 
These are most commonly seen at the posterior pole, though they may 
occur anywhere in the retina. At least one quarter of the retina must be non-
perfused prior to the development of proliferative changes. They appear as 
irregular vessels, often forming networks which may be accompanied by fibrous 
tissue. Neovascularisation at the disc (NVD) is neovascularisation on or within 
one disc diameter of the optic disc, while neovascularisation elsewhere (NVE) is 
present away from the optic disc. Neovascularisation of the iris (NVI) may also 
develop which has a high risk for the development of neovascular glaucoma.  
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12. Changes in Vitreous 
Posterior vitreous detachment may occur. New vessels on the retina are 
adherent to the posterior vitreous surface. As the vitreous starts separating, these 
vessels are stretched and may result in bleeding into the vitreous cavity. Pre-
retinal haemorrhages may also break into the vitreous. Vitreous condensation and 
fibrosis may also occur.  
13.   Tractional Retinal detachment  
Tractional retinal detachment may occur due to the contraction of 
fibrovascular membranes. The extent and location of tractional retinal 
detachment depends on vitreo-retinal attachments. 
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CLINICAL EVALUATION 
1. Best Corrected Visual Acuity  
Visual loss mainly depends on the involvement of the macula in the form 
of edema, haemorrhage, exudates, ischemia or traction. Other causes of vision 
loss include vitreous haemorrhage, tractional retinal detachment, neovascular 
glaucoma. ETDRS chart is mainly used in western countries whereas Snellen 
chart is widely used in developing countries like India.  
2. Intra ocular pressure  
IOP should preferably be measured with applanation tonometer to rule out 
glaucoma, especially neovascular glaucoma. 
3. Anterior segment Examination using slit lamp examoination 
Anterior segment examination is carries out routinely with special 
emphasis on media opacities which may preclude fundus view and 
neovascularisation of iris. 
4. Fundus examination using Indirect Ophthalmoscopy and slit lamp 
biomicroscopy with 90 D lens  
This technique allows the examiner to integrate the view of the entire retina 
with good stereopsis. Dilated fundus examination is mandatory in each visit. 
 
5.   Direct Ophthalmoscopy  
Though the area of retina examined is smaller, the increased magnification 
of this method allows detailed examination of the various retinal lesions.  
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6.   Fundus Photography  
The ETDRS classification used 7 standard photographic fields. It is useful 
for documentation of lesions and during follow up.  
7.   Fundus Fluorescein Angiography  
This is one of the essential investigations needed in diabetic retinopathy.  
It can demonstrate  microaneurysms,  intraretinal microvascular abnormalities, 
new vessels and the extent of capillary closure. It provides the earliest evidence 
of a breach in the blood retinal barrier. Macular oedema can also be detected on 
FFA and classified into the focal, diffuse or ischemic variety. In eyes with 
asteroid hyalosis or hazy media, FFA may reveal lesions previously undetected 
on fundus examination.  
8.   Optical Coherence Tomography  
It enables detection and quantification of macular edema and vitreo-
macular traction. By OCT, diabetic macular edema is classified into spongy, 
serous, cystoid, taut posterior hyaloid and vitreo-macular traction. The central 
macular thickness is used routinely to guide the decisions regarding the treatment 
modalities.  
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MANAGEMENT OF DIABETIC RETINOPATHY 
The first step in the management of diabetic retinopathy is strict control of 
blood sugar as shown by Diabetic Control and Complications Trial (DCCT).  The 
treatment proper can be divided into that for non-proliferative retinopathy, 
proliferative retinopathy and diabetic macular edema. 
Management of Non-proliferative retinopathy: 
 The treatment of non-proliferative retinopathy involves modification of 
systemic risk factors including glycemic control, blood pressure, serum lipid 
levels is critical for the management of mild and moderate NPDR. Provided 
careful follow-up can be maintained, PRP is not recommended for eyes with mild 
or moderate NPDR since the benefits are small and the risks are equivalent as 
compared with treating more severe retinopathy.  
Management of proliferative diabetic retinopathy: 
 Diabetic Retinopathy Study proved very quickly that severe visual loss 
(visual acuity < 5/200) occurred 60% less frequently in eyes treated with 
photocoagulation than in eye assigned to no treatment. ETDRS recommends pan 
retinal photocoagulation for all patients approaching the high risk stage.  
Pan retinal Photocoagulation: 
 As the name suggests, PRP is based on the principle of photo coagulation. 
The beneficial effects of laser photocoagulation are destruction of ischemic retina 
thus reducing the angiogenic stimulus and increase in oxygen supply from 
choroid to inner retina through the laser scars. PRP is commonly delivered 
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through trans-pupillary slit lamp delivery system. It can also be delivered through 
indirect ophthalmoscope or endolaser probe. Argon green is the most commonly 
used wavelength, although various other lasers like dye yellow, krypton red, solid 
state diode lasers are also used. It is usually given under topical anaesthesia. The 
lenses used for slit lamp delivery include the Rodenstock panfunduscopic lens, 
the Volk quadraspheric lens, and the Goldmann three-mirror lens. 
 Spot size depends on the lens selected, usually 500 mm for the Goldmann 
lens and 200 mm for the Rodenstock lens, to achieve 500mm burn. The duration 
is 0.1–0.2 s. The power should be titrated to produce a gray-white burn. The DRS 
protocol specified 800–1600 spots. The burns should be placed 1–1.5 burn widths 
apart. Pan retinal treatments are usually divided over two to three sessions. 
Complications include loss of peripheral visual field, loss of dark adaptation, loss 
of accommodation, corneal abrasions, optic nerve damage, choroidal detachment, 
exudative retinal detachment, choroidal neovascular membranes, macular edema, 
vitreous haemorrhage etc. 
 Anti-VEGF agents: 
 Intravitreal anti-angiogenic agents can induce rapid initial reduction of 
ocular neovascularization but the effect generally appears to be temporary, 
requiring additional definitive treatment such as laser photocoagulation. Most 
widely used agents are bevacizumab, ranibizumab, pegabtanib etc. 
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Pharmacologic vitreolysis: 
 The presence of complete posterior vitreous detachment in patients with 
diabetic retinopathy has been found to be associated with lower risk of 
progression to PDR. Intravitreal injections of pharmacologic agents like plasmin, 
tissue plasminogen activator, microplasmin, hyaluronidase, chondroitinase etc. 
can be used to induce complete PVD.  
Management of diabetic macular edema: 
 After the diagnosis of clinically significant macular edema is made, the 
patient should undergo fundus fluorescein angiography to rule out ischemic 
maculopathy and OCT to detect vitreo-macular traction and taut posterior hyaloid 
and to quantify the edema. With serous or spongy edema with thickness less than 
250-300 microns, the treatment would be grid or focal laser based on whether 
edema is diffuse or focal in FFA. In case of ischemic maculopathy, laser is 
deferred and no treatment is of much help. In case of cystoid macular edema, 
laser does not work, hence treated with intravitreal anti-VEGF or intravitreal 
steroids. Vitreo macular traction and taut posterior hyaloid are managed by 
vitrectomy.  
Vitrectomy: 
 The Diabetic Retinopathy vitrectomy study suggested that visual outcome 
was better in patients who underwent early vitrectomy than those who were 
conventionally managed. The proportion with very poor visual outcome was 
similar in the two groups. The advantage of early vitrectomy tended to increase 
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with increasing severity of new vessels. The indications of Vitrectomy include 
organized vitreous hemorrhage, tractional retinal detachment, vitreo-macular 
traction and taut posterior hyaloid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
 
ELECTRORETINOGRAM 
Introduction  
Electro retinogram is an objective method of evaluating retinal function. It 
is the corneal measure of an action potential produced by the retina, when it is 
stimulated by light of adequate intensity. Holmgren in 1865 was the first to show 
an alteration in electrical potential by flash of light. 
Components of ERG: 
a-wave: 
Initial corneal negative wave is called “a” wave. It arises from 
photoreceptor layer.  
b-wave: 
Large corneal positive wave following a wave. It arises from Muller’s cells 
which respond to extracellular potassium released by the activity of bipolar cell 
layer.  
Oscillatory potentials (OPs): 
Oscillatory potentials are seen as a series of three or four rhythmic wavelets 
having almost equal intervals of about 6.5 milliseconds in the ascending limb of 
b wave. OPs reflect the activity of feedback synaptic circuits within the retina and 
represent a modulating effect of amacrine cells on the b wave.  
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c-wave: 
Prolonged positive wave represents the function of retinal pigment 
epithelium. It represents only Rod activity. 
d-wave:  
It is an off response. It occurs due to change in potential when light 
stimulus is turned off.  
Measurements of ERG components are amplitude, latency and implicit time. 
Amplitude: Amplitude of “a” wave is measured from baseline to the trough of the 
“a” wave and that of b wave is measured from the trough of the “a” wave to the 
peak of the b wave. 
Latency: Time interval between the onset of stimulus and beginning of the “a” 
wave response. 
Implicit Time: Time from the onset of the light stimulus until the maximum “a” 
wave or b wave response. 
TYPES OF ERG 
Depending upon stimulus zone, it is classified as Full field ERG, Focal 
ERG and Multi focal ERG. Depending upon type of stimulus, it is divides into 
Single flash ERG, Flicker fusion ERG, Bright red ERG, Dim blue filter ERG and 
Pattern ERG. Depending on state of retinal adaptation, it is classified as Scotopic 
ERG, Mesopic ERG and Photopic ERG. 
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ERG RECORDING 
I.ELECTRODE 
Active electrode used include Contact lens electrodes like Unipolar-jet 
electrode and some of the Bipolar electrode–burian allen electrode & Non-contact 
lens electrode like Gold foil, h-k loop, and DTL fiber. One reference electrode is 
placed on patient's forehead and one ground electrode is placed on the ear.  
II. ILLUMINATION 
 Ganzfield bowl with a stroboscope flash, or cathode ray tube or light 
emitting diodes provide the stimulus flash. Peak wavelength sensitivity for rods 
is around 510 nm and the peak sensitivity of cones is about 560 nm.  
III. RECORDING PROTOCOLS 
Scotopic trial: Pupils are dilated and dark adapted retina for 15 minutes. 
Step 1: Red flash dark adapted trial 
Step 2: Blue filter dark adapted trial 
Step 3: White light dark adapted trial 
Produces large amplitude, longer implicit time/6 – 8 million cones & 125 million 
rods 
Photopic trial: Gradually light adapted retina from dark lamp to room light to 
Ganzefeld bowl. 
Step 4: Red flash light adapted trial 
Step 5: White flash light adapted trial 
Step 6: White flash test for oscillatory potential 
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Step 7: 30 Hz flicker test 
Produces low amplitude, shorter implicit time/4- 8 million cones. 
IV. SEPERATING ROD AND CONE ERG 
Responses from rods and cones can be separated by altering retinal 
adaptation status, background illumination and brightness & colour of the light 
stimulus. Rods and cones differ in number, peak color sensitivity, threshold and 
recovery. Cone response is obtained in a light adapted state and stimulation with 
bright red light. Isolated rod response is obtained in a dark adapted state with a 
dim blue stimulation. Combined response is obtained in a scotopic ERG with a 
bright flash of light. 
CLINICAL UTILIZATION:  
 ERG is widely used as in the diagnosis of rod dystrophies like retinitis 
pigmentosa and congenital stationary night blindness, cod dystrophies, vascular 
disorders like diabetic retinopathy and venous occlusions, drug toxicities., etc. It 
is sometimes used as a prognostic tool in trauma regarding retinal function. 
MULTIFOCAL ERG 
 Erich Sutter adapted the mathematical sequences called binary m-
sequences creating a program that can extract hundreds of focal ERGs from a 
single electrical signal. This system allows assessment of ERG activity in small 
areas of retina. With this method one can record mfERGs from hundreds of retinal 
areas in a several minutes. Small scotomas in retina can be mapped and degree of 
retinal dysfunction quantified. 
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ROLE OF ERG IN DIABETIC RETINOPATHY: 
Alterations in oscillatory potentials have been shown to predict the onset 
of proliferative retinopathy better than vascular lesions seen on fundus .The 
oscillatory potential (OP) components (OP1-OP4) were significantly reduced in 
amplitude and increased in implicit time in the NPDR patients. The amplitude of 
the b-wave of the scotopic full-field (flash) ERG, reflecting largely the activity 
of the bipolar cells are abnormal in diabetes in the absence of visible fundus signs 
of retinopathy. Focal ERGs can also be a sensitive indicator of macular function 
in eyes with diabetic maculopathy. In some eyes at the early stage of diabetic 
maculopathy, the macular OPs were selectively reduced leaving the a- and b-
waves intact.  
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FACTORS INFLUENCING PROGRESSION OF DIABETIC 
RETINOPATHY 
The factors which influence the progression of diabetic retinopathy can be 
classified into systemic and ocular. 
SYSTEMIC FACTORS:  
GLYCEMIC CONTROL:  
 Retrospective studies evaluating long term control of blood glucose 
and its impact on retinopathy have suggested that hyperglycaemia is closely 
associated with the development and progression of retinopathy.  
According to the Diabetic Control and Complications Trial (DCCT), a 10% 
decrease in HbA1c (from 8% to 7.2%) results in a decrease in incidence of 
diabetic retinopathy by 35% to 40%. The results of the DCCT are as follows:  
 Intensive therapy reduced the first appearance of any retinopathy by 27% 
and clinically meaningful diabetic retinopathy by 35 to 74%.  
 Intensive therapy also reduced the development of other microvascular 
complications such as reduction of microalbuminuria by 35%, clinical 
proteinuria by 56% and clinical neuropathy by 60%.  
 Intensive treatment included insulin administration at least thrice daily 
with dose adjustment on the basis of self blood glucose monitoring with 
aim of achieving normoglycaemia. However this study was based on the 
results obtained from patients suffering from IDDM and not NIDDM. 
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The UKPDS enrolled only type II diabetic patients. It evaluated glycaemic 
control attained with either insulin or sulphonyl urea and its effect on retinopathy. 
The study stated that intensive blood glucose control reduced the incidence and 
progression of retinopathy and also the development of other microvascular 
complications of diabetes. These studies emphasized the importance of achieving 
the ADA guidelines of a target HbA1c levels below 7% and suggest that the 
earlier this level is achieved, the lower the risk for development and progression 
of retinopathy.  
HYPERTENSION: 
 Hypertension is more common in type 2 diabetes, and in the UKPDS 38% 
of newly diagnosed patients with type 2 diabetes had hypertension. Due to the 
impaired auto regulatory capacity of retinal vasculature in diabetic retinopathy, 
high blood pressures leads to increased pressures in retinal capillaries aggravating 
macular edema (7). It has been shown that hypertension plays a key role both in 
the incidence and progression of diabetic retinopathy.  The UKPDS is the first 
report in patients with type 2 diabetes to show conclusively that tight blood 
pressure control reduces the risk of clinical complications from diabetic eye 
disease (12).  The EUCLID study suggested that ACE inhibition was associated 
with a statistically significant reduction in progression of retinopathy. 
NEPHROPATHY: 
 In the WESDR, proteinuria was very strongly associated with severe 
retinopathy in the younger-onset diabetics with 10 years or more of diabetes. 
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Adult-onset diabetics with proteinuria were also more likely to have proliferative 
retinopathy. Renal retinopathy will overlie diabetic retinopathy in uremic patients 
and consists of a hypertensive component and a uremic component. 
SEVERE ANEMIA: 
 Severe anemia, if present may be associated with increased risk of severe 
retinopathy, as suggested by ETDRS and other studies. One small series reported 
better clearance of hard exudates and improvement in BCVA in patients after 
successful treatment of severe anemia with erythropoietin (7).  
PREGNANCY: 
 The role of pregnancy in the progression of diabetic retinopathy remains 
somewhat controversial. Klein and co-workers reported on a prospective case-
control study comparing pregnant and non-pregnant insulin-taking diabetic 
women. Risk factors that were evaluated for the progression of retinopathy 
included glycosylated hemoglobin, duration of diabetes, current age, diastolic 
blood pressure, number of past pregnancies, and current pregnancy. It has been 
postulated that progression of retinopathy during pregnancy may be at least partly 
related to the rapid tightening of metabolic control. Improvement in metabolic 
control should be gradual. Diabetic patients taking insulin are known to be at 
increased risk of an adverse pregnancy outcome, including abortion, perinatal 
death, and severe congenital anomalies (46, 47). 
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DRUGS: 
 Diuretics were associated with increasing severity of diabetic retinopathy. 
Inhibitors of Renin- Angiotension system, aldose reductase inhibitors, Protein 
kinase C inhibitors, Statins are implicated in halting the progression of diabetic 
retinopathy. Thiazolidinediones were associated with increased incidence as well 
as worsening of macular edema (7). 
OCULAR FACTORS: 
   The ocular factors associated with increased incidence and progression of 
retinopathy are reduced arteriole/ venule ratio, presence of A/V nicking and focal 
arteriolar narrowing (7). Presence of myopic degeneration, glaucoma and other 
retinal degenerations due to trauma / inflammation protect against progression of 
retinopathy.  
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SCREENING SCHEDULE FOR OPHTHALMIC EVALUATION OF 
DIABETIC PATIENTS 
 
Type of 
diabetes 
Timing of first eye 
examination  
Follow up interval  
recommended  
Type 1 Within 5 years of the 
diagnosis  
Every 1 year  
Type 2   At the time of diagnosis  Every 1 year  
Any  type  with  
pregnancy 
Before conception or in  
the  early  first trimester 
Every 1-3 months in severe  NPDR,  
early PDR or high risk PDR ; 
Every 3-13 months in patients  with  no 
retinopathy or mild or  
moderate NPDR  
 
 ETDRS RECOMMENDATION FOR FOLLOW-UP 
 
 
CATEGORY FOLLOW UP 
No diabetic retinopathy   Review in 12 months  
Mild NPDR   Review range of 6-12 months, depending on stability, 
severity and associated systemic features  
Moderate NPDR Review  in  approximately  6 months  
Severe NPDR Review in 4 months  
Very severe   Review in 2-3 months  
Early PDR   Treatment considered according to stability, severity and 
associated systemic factors. If the patient is not treated, 
review in 2 months. 
High-risk PDR   Treatment should be performed immediately if possible 
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PART II 
 
AIM & OBJECTIVES 
 Aim                
 To analyze the role of oscillatory potentials of ERG and other factors like 
glycemic status and blood pressure in predicting progression of diabetic 
retinopathy. 
 
Primary objective 
To find out the association between the factors like oscillatory potentials 
in ERG,  glycemic status (as measured by fasting blood sugars), blood pressure 
(systolic and diastolic) and progression of diabetic retinopathy. 
   
Secondary Objective 
To find out other abnormalities in ERG parameters that occur in various 
stages of diabetic retinopathy like delayed b wave implicit times. 
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MATERIALS AND METHODS 
This prospective observational study was conducted in Regional Institute 
of Ophthalmology – Government Ophthalmic Hospital, Egmore, Chennai for a 
period of 12 months.  
 
Subject Selection 
50 patients based on inclusion criteria will be registered, evaluated and 
followed up subsequently for 12 months. 
 
Inclusion criteria  
Patients with Type I or II diabetes who have been diagnosed as Moderate, 
severe and very severe non proliferative diabetic retinopathy with or without 
macular edema (according to ETDRS classification). 
Exclusion criteria 
Proliferative diabetic retinopathy, Venous and arterial occlusion, Post  
Pan retinal photocoagulation status, Post anti-VEGF injection status, Patients 
with posterior Uveitis and glaucoma. 
Procedure 
History: 
 All patients were screened with a detailed history including type & 
duration of diabetes, diet history and history about physical activity. History of 
treatment with oral hypoglycemic agents, insulin and other drug intake was 
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elicited. History of systemic comorbidities like hypertension, coronary artery 
disease etc. and their treatment was enquired about. Previous ophthalmic 
surgery/laser or other medical treatment history was also taken. 
All patients then underwent a thorough systemic and ocular examination.  
GENERAL EXAMINATION  
General vital data like pulse, systolic and diastolic blood pressure, 
peripheral pulses were noted. Systemic examination of CNS, CVS, RS and 
abdomen was done. 
OCULAR EXAMINATION  
Visual acuity (by Snellen’s chart) and refraction were measured. Anterior 
segment evaluation was done with slit lamp biomicroscopy. Intraocular pressure 
was measured using Applanation tonometry. Diabetic retinopathy was evaluated 
by a dilated fundus examination using 90D & indirect ophthalmoscopy. Fundus 
photographs were taken for documentation and the levels of retinopathy will then 
be classified as per the ETDRS. All patients underwent Fundus fluorescein 
angiography and OCT to assess maculopathy if present. 
INVESTIGATIONS 
 Fasting blood sugars was measured. All patients underwent full field 
Electroretinogram with special emphasis on oscillatory potentials.  
Follow up Visits:  
Every month. During follow up visits- Fasting blood sugar levels, blood 
pressure, visual acuity, intra ocular pressure, slit lamp biomicroscopy (anterior 
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segment & fundus with + 90 D), direct and ophthalmoscopy done. Any 
progression of diabetic retinopathy is documented. 
Assessments of Parameters:   
 Progression of diabetic retinopathy 
 ERG – Oscillatory Potentials 
 Fasting blood sugar levels 
 Blood pressure (systolic & diastolic) 
V. RESULTS: 
1. Progression of diabetic retinopathy in patients with normal and abnormal 
oscillatory potentials. 
2. Influence of baseline FBS over progression of retinopathy 
3. Association of systolic and diastolic blood pressures with progression of 
retinopathy in diabetes. 
4. A note of other ERG abnormalities in diabetic retinopathy. 
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CASES 
 
1.  A patient with BE severe NPDR with CSME 
 
 
 
 
2. A patient with moderate NPDR with CSME 
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3. A patient with PDR. 
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ERG SHOWING ABNORMAL OSCILLATORY 
POTENTIALS 
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OBSERVATION AND RESULTS 
 
I. Age distribution 
 
 
In this study, most common (34 %) age group presented was 56 to 60 years 
followed by 60 to 65 years (16 %). The least common age group presented was 
36 to 40 years (2 %). The mean age at presentation was 57.22 ±7.86 years. 
 
 
 
II. Sex distribution 
 
Sex distribution No. of patients 
Female 28 (56 %) 
Male 22(44%) 
Total 50 
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AGE CATEGORY
Age 
category 
(years) 
36 to 40  41 to 45  46 to 50  51 to 55  56 to 60  61 to 65  66 to 70  Total 
No. of 
patients 
1(2%) 4(8%) 7(14%) 6(12%) 17(34%) 8(16%) 7(14%) 50 
49 
 
 
Out of 50 patients participated in the study, 26 were females and 22 were males.  
 
 
 
 
 
 
III. Baseline Retinopathy levels          
              
Baseline retinopathy BE No. of patients 
MODERATE NPDR 15(30%) 
SEVERE NPDR 17(34%) 
VERY SEVERE NPDR 18(36%) 
Grand Total 50 
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            In this study, 30% of the patients had moderate non proliferative 
diabetic retinopathy, 34 % had severe non proliferative diabetic retinopathy and 
the remaining 36 % had very severe NPDR.  
 
              
IV. Age Category Vs Baseline Retinopathy 
 
Age category/ 
Retinopathy 
MODERATE 
NPDR 
SEVERE 
NPDR 
VERY SEVERE 
NPDR 
Total 
36 to 40 Years 0 1 0 1 
41 to 45 Years 2 1 1 4 
46 to 50 Years 3 2 2 7 
51 to 55 Years 3 0 3 6 
56 to 60 Years 5 7 5 17 
61 to 65 Years 1 3 4 8 
66 to 70 Years 1 3 3 7 
Total 15 17 18 50 
  
             In this study, maximum number of patients in all the three retinopathy 
groups belonged to 56 to 60 years age group. The mean age at presentation of 
patients with moderare, severe and very severe NPDR were 55.01 ± 7.54 years, 
58 ± 8.27 years and 58.28 ± 7.81 years respectively. 
 
         
 
V. Duration of Diabetes 
 
Duration (years) 0-5 Y 6-10 Y 11-15 Y 16-20 Y >20 Y Total 
No. of patients 18(36%) 19(38%) 7(14%) 5(10%) 1(2%) 50 
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 Around 38% of the patients had diabetes for a period of 6-10 years in this 
study followed by 36 % in 0-5 year’s duration. Only 2 % had diabetes for a period 
more than 20 years. 
 
 
              
VI. Baseline Retinopathy Vs Duration of diabetes 
 
Baseline Retinopathy / 
Duration of DM 
0-5 Y 6-10 Y 11-15 Y 16-20 Y >20 Y Total 
MODERATE NPDR 12(80%) 3(20%) 0 0 0 15 
SEVERE NPDR 4(23.52%) 9(52.91%) 1(5.9%) 2(11.77%) 1(5.9%) 17 
VERY SEVERE NPDR 2(11%) 7(39%) 6(33%) 3(17%) 0 18 
Total 18 19 7 5 1 50 
             
 
     In this study, about 80 % of the patients with moderate NPDR had diabetes for 
a period less than 5 years and remaining 20 % had 6-10 years of diabetes. Most 
common Duration of diabetes in patients with severe NPDR was 6-10 years 
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(52.91%) followed by 0-5 years (23.52%). Patients with very severe NPDR had 
diabetes for 6-10 years most commonly (39 %) followed by 11-15 years (33 %). 
 
 
 
 
 
VII. Treatment of Diabetes Milletus 
 
In this study, most of the patients (72%) were treated with oral 
hypoglycemic agents for diabetes. Around 24 % of the patients were treated with 
oral hypoglycemic agents and insulin injections. Only 4 % of the patients were 
not under any treatment for diabetes. 
 
Treatment of DM NONE OHA OHA & Insulin Total 
No. of patients 2(4%) 36(72%) 12(24%) 50 
3
9
7
2
3
1
6
12
4
2
0
2
4
6
8
10
12
14
MODERATE NPDR SEVERE NPDR VERY SEVERE NPDR
N
O
. O
F 
P
A
TI
EN
TS
BASELINE RETINOPATHY
BASELINE RETINOPATHY Vs DURATION OF DM
6-10 Y
16-20 Y
11-15 Y
0-5 Y
  >20 Y
53 
 
 
             
 
VIII. Treatment of DM Vs Baseline Retinopathy 
   
Baseline retinopathy 
/ Treatment of DM 
MODERATE 
NPDR 
SEVERE 
NPDR 
VERY SEVERE 
NPDR 
Total 
NONE 1(6.67%) 0 1(5%) 2 
OHA 13(86.66%) 14(82%) 9(50%) 36 
OHA & Insulin 1(6.67%) 3(18%) 8(45%) 12 
Total 15 17 18 50 
 
Around 87% of the patients with moderate NPDR, 82 % of the severe 
NPDR group and 50 % of the very severe NPDR group in this study were under 
treatment with oral hypoglycemic agents alone, whereas 45 % of the very severe 
NPDR group, 18 % of the severe NPDR group and 6 % of the moderate NPDR 
group were treated with a combination of oral hypoglycemic agents and insulin 
injection. 6% of moderate NPDR group and 5 % of very severe NPDR group 
were not under treatment. 
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IX. Systemic comorbidities 
 
Systemic comorbidities / 
Retinopathy 
MODERATE 
NPDR 
SEVERE 
NPDR 
VERY SEVERE 
NPDR 
Total 
Coronary Artery Disease 0 3 3 6(12%) 
Hypertension 7 9 8 24(48%) 
Nephropathy 0 2 5 7(14%) 
None 7 3 2 12(24%) 
Stroke 1 0 0 1(2%) 
Total 15 17 18 50 
 
     In this study, Hypertension was the most common systemic comorbidity 
found in 48 % of the patients. Around 24 % of the patients had no systemic illness, 
14% had nephropathy, 6 % had coronary artery disease and 2 % had stroke. 47 % 
of patients in moderate NPDR, 53 % of severe group and 44 % of very severe 
NPDR group were hypertensive. Around 12 % of severe group and 28 % of very 
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severe NPDR group had nephropathy at baseline. 18 % of severe group and 17 % 
of very severe NPDR group had coronary artery disease. 
1 patient in moderate NPDR group had a previous attack of stroke. The rest had 
no complications. 
 
 
 
 
 
 
X. Fasting Blood Sugar 
 
FBS (mg/dL) No. of patients 
< 100 12(24%) 
100-119 24(48%) 
120-149 12(24%) 
150-200 2(4%) 
Grand Total 50 
 
                    In this study, 48 % of the patients had their fasting blood sugar level 
between 100-119 mg/dL followed by 24 % each in <100 mg/dl and 120-149 
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mg/dl groups and 4 % in the 150-200 range. The mean Fasting blood sugar in the 
study was 112.56 ± 18.63 mg/dL. 
 
 
 
 
 
XI. Fasting Blood sugar Vs Baseline Retinopathy 
 
Baseline Retinopathy 
/ FBS (mg/dL) 
< 100 100-119 120-149 150-200 Total 
MODERATE NPDR 6(40%) 9(60%) 0 0 15 
SEVERE NPDR 1(6%) 10(59%) 6(35%) 0 17 
VERY SEVERE 
NPDR 
5(28%) 5(28%) 6(33%) 2(11%) 18 
Total 12 24 12 2 50 
 
                 About 60% of the patients in this study with moderate NPDR had 
fasting blood sugar in the range of 100-119 mg/dl and the remaining 40% had 
FBS < 100 mg/dl. In the severe NPDR group, 59% of the patients’ FBS was 
between 100-119 mg/dL, 35 % had FBS in the range of 120-149 mg/dL and 6 % 
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had <100 mg/dL. 33 % of patients with very severe NPDR had their fasting blood 
sugar levels between 120-149 mg/dL whereas 28 % fall in the group of 100-119 
mg/dL, another 28 % in <100 mg/dL and about 11 % had FBS in the range of 
150-200 mg/dL. The average fasting blood sugar in the moderate NPDR, severe 
NPDR and very severe NPDR were 102.47 ± 7.79 mg/dL , 113.35 ± 12.74 mg/dL  
and 120.22 ± 25.40 mg/dL respectively. 
                    
 
 
 
 
 
XII. Systolic Blood Pressure 
 
Systolic Blood Pressure 
(mm of Hg) 
<120 120-139 140-159   ≥160       Total 
No. of Patients 8(16%) 23(46%) 18(36%) 1(2%) 50 
 
      In this study, 46 % of the patients had their systolic blood pressure in the 
range of 120-139 mm of Hg, 36 % in the range of 140-159 mm of Hg, 16% had 
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their systolic BP <120 mm of Hg and the remaining 2 % had BP ≥ 160 mm of 
Hg. The mean systolic BP was 129.60 ± 12.77 mm of Hg. 
 
 
 
 
 
XIII. Systolic blood Pressure Vs Baseline Retinopathy  
 
The mean systolic blood pressure in moderate, severe and very severe 
NPDR were 120.67 ± 11.63, 134.12 ± 12.78, 132.78 ± 10.18 mm of Hg 
respectively. About 53 % of the patients with moderate NPDR, 41 % of severe 
NPDR group and 44 % of very severe NPDR group had their systolic BP in the 
range of 120-139 mm of Hg. 40 % of moderate NPDR patients, 6% of severe 
NPDR group and another 6% of very severe NPDR group fell in the <120 mm of 
Hg group. 7% of moderate NPDR patients, 47 % of severe NPDR patients and 50 
% of very severe group had 140-159 mm of Hg. Around 6 % of patients in severe 
NPDR group had their systolic BP ≥160 mm of Hg group.  
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Retinopathy Vs 
Systolic BP(mm of Hg) 
<120 120-139 140-159  ≥160 Total 
MODERATE NPDR 6(40%) 8(53%) 1(7%) 0 15 
SEVERE NPDR 1(6%) 7(41%) 8(47%) 1(6%) 17 
VERY SEVERE NPDR 1(6%) 8(44%) 9(50%) 0 18 
Total 8 23 18 1 50 
       
                
 
 
 
 
 
XIV. DIASTOLIC BLOOD PRESSURE 
 
Diastolic Blood Pressure 
(mm of Hg) 
No. of patients 
<80 11(22%) 
80-89 23(46%) 
90-99 14(28%) 
 ≥100 2(4%) 
Total 50 
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              In this study, around 46% of the patients had diastolic BP in the range of  
80-89 mm of Hg followed by 28% in 90-99 mm of Hg, 22 % in <80 mm of Hg 
and 4 % in  ≥ 100 mm of Hg. The mean diastolic BP was 82.6 ± 8.53 mm of Hg.   
 
 
 
XV. Diastolic BP Vs Baseline Retinopathy 
 
Diastolic BP (mm of 
Hg) / Baseline 
retinopathy 
<80 80-89 90-99  ≥100 Total 
MODERATE NPDR 4(27%) 9(60%) 2(13%) 0(%) 15 
SEVERE NPDR 5(29%) 5(29%) 6(36%) 1(6%) 17 
VERY SEVERE NPDR 2(11%) 9(50%) 6(33%) 1(6%) 18 
 Total 11 23 14 2 50 
 
The mean diastolic blood pressure in moderate, severe and very severe 
NPDR was 80 ± 6.55 mm of Hg, 85.29 ± 7.99 mm of Hg and 84.44 ± 7.05 mm 
of Hg respectively. In the moderate NPDR group, 60 % of the patients had 
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diastolic BP in the range of 80-89 mm of Hg, 27 % of the patients’ diastolic BP 
was < 80 mm of Hg and 13 % in the range of 90-99 mm of Hg group. About 36 
% of the patients with severe NPDR had their diastolic BP in the range of 90-99 
mm of Hg, 29 % of the patients fell in the <80 mm of Hg group, another 29 % of 
patients fell in the 80-89 mm of Hg and the remaining 6 % had their diastolic BP 
> 100 mm of Hg. In very severe NPDR category, 50% of the patients fell in the 
80-89 mm of Hg group, 33 % had their systolic BP in the range of 90-99 mm of 
Hg, 11 % fell in <80 mm of Hg group and remaining 6 % had diastolic BP >100 
mm of Hg. 
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XVI. Baseline Visual Acuity BE 
 
            The mean baseline visual acuity in RE was 0.51 (~6/18) log MAR units. 
Around 52 % of the patients presented with a baseline visual acuity in the range 
of 6/6 – 6/18 (0-0.48) followed by 44 % of patients in the range of <6/18 – 6/60 
(>0.48-1) and the remaining 4 % fell in the group of <6/60-3/60(>1-1.30) in RE. 
The mean baseline visual acuity in LE in this study was 0.48 ± 0.31 (6/18) 
logMAR units. Nearly half of the patients (~52 %) had BCVA in the range of 6/6-
6/18 (0-0.48) at presentation whereas the rest (48 %) of patients had BCVA in the 
range of <6/18-6/60 (>0.48 - 1) at presentation in LE. 
 
Baseline BCVA RE LE 
6/6-6/18 (0-0.48) 26(52%) 24(48%) 
 <6/18-6/60 (>0.48-1) 22(44%) 26(52%) 
<6/60-3/60 (>1-1.30) 2(4%) 0 
Total 50 50 
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XVII. Baseline Maculopathy 
 
Baseline Maculopathy/ No. 
of patients 
CSME NORMAL TOTAL 
RE 29(58%) 21(42%) 50 
LE 30(60%) 20(40%) 50 
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            In this study, about 58% of the patients presented with clinically 
significant macular edema in RE and 60 % of the patients presented with CSME 
in LE. 
 
 
  
  
XVIII. OSCILLATORY POTENTIALS 
 
Oscillatory potentials/ 
No. of patients 
OP NORMAL OP 
ABNORMAL 
Grand Total 
BE 28(56%) 22(44%) 50 
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        In this study, around 44 % of patients had abnormal oscillatory potentials in 
BE and 56 % of patients had normal oscillatory potentials in BE. 
 
XIX. Oscillatory Potentials Vs Baseline retinopathy BE 
 
Oscillatory Potentials / 
Baseline Retinopathy 
OP 
NORMAL 
OP 
ABNORMAL 
Total 
MODERATE NPDR 11(73%) 4(27%) 15 
SEVERE NPDR 10(59%) 7(41%) 17 
VERY SEVERE NPDR 7(39%) 11(61%) 18 
Total 28 22 50 
 
     
 In this study, 73% of the patients with moderate NPDR in BE had normal 
oscillatory potentials while 27% had abnormal OPs. In severe NPDR group, 59 
% had normal OPs and 41 % had abnormal OPs whereas 61% of very severe 
NPDR patients had abnormal OPs and 39 % had normal OPs. 
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XX. Other ERG abnormalities 
 
ERG abnormalities DELAYED b- IT NORMAL Grand Total 
BE 12(24%) 38(76%) 50 
 
       In this study, 24 % of patients had delayed b wave implicit time in BE and 
76 % had no such findings.   
 
 
 
 
XXI. Other ERG abnormalities Vs Baseline Retinopathy BE 
 
 
ERG abnormalities BE / 
Baseline Retinopathy BE 
DELAYED b- IT NORMAL Total 
MODERATE NPDR 0 15(100%) 15 
SEVERE NPDR 4(24%) 13(76%) 17 
VERY SEVERE NPDR 8(44%) 10(56%) 18 
Total 10 40 50 
 
          
In this study, all patients with moderate NPDR in BE had normal ERG. 
About 24% of patients with severe NPDR in BE and 44% of patients with very 
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severe NPDR had delayed b wave implicit times. The remaining patients in the 
two groups had normal ERG.  
 
 
 
XXII. Treatment of Maculopathy 
 
Maculopathy Treatment/ No. of patients RE LE 
GR + ANTI-V 9(18%) 10(20%) 
GRID LASER   20(40%) 20(40%) 
NONE 21(42%) 20(40%) 
Grand Total 50 50 
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 In this study, 18 % of patients received grid laser with anti-VEGF 
injections for CSME in RE and 20% received the same treatment in LE. 40 % of 
the patients received grid laser as treatment each in RE and LE.  
 
XXVI.  Retinopathy at the end of the study BE 
 
 
BE Retinopathy 
at the end 
MODERATE 
NPDR 
SEVERE 
NPDR 
VERY 
SEVERE 
NPDR 
  PDR Total 
No. of patients 11(22%) 13(26%) 16(32%) 10(20%) 50 
 
      In this study, around 32% of the patients were diagnosed to have Very severe 
NPDR followed by 26% had severe NPDR, 22% had moderate NPDR and 20% 
were diagnosed to have proliferative diabetic retinopathy at the end of the study. 
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XXVII. Maculopathy at the end of the study 
 
Maculopathy at the 
end/ No. of patients 
CSME TREATED 
CSME 
NORMAL TOTAL 
RE 7(14%) 29(58%) 14(28%) 50 
LE 6(12%) 30(60%) 14(28%) 50 
 
     In this study, about 58 % and 60% of patients had their CSME treated at the 
end of the study in RE and LE respectively. 28 % of patients had normal macula 
at the end in RE and 28 % had normal macula in LE. 14 % of patients had CSME 
in RE and 12% of patients were found to have CSME in LE. 
 
 
 
 
XXVIII. BCVA AT THE END BE 
 
 
FINAL BCVA 6/6-6/18 <6/18-6/60 TOTAL 
RE 35(70%) 15(30%) 50 
LE 38(76%) 12(24%) 50 
TOTAL 73 27 100 
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       In this study, 70 % and 76 % of patients had BCVA at the end in the range 
of 6/6-6/18 in RE and LE respectively. About 30 % of patients in RE and 24% of 
patients in LE had final BCVA of <6/18-6/60. 
 
 
 
XXIX.  PROGRESSION OF DR BE 
 
PROGRESSION OF DR No. of patients 
YES 22(44%) 
NO 28(56%) 
Total 50 
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Around 56% of the patients participated in the study did not progress to 
next stage of diabetic retinopathy. The remaining 44% progressed to next level 
of diabetic retinopathy. 
 
 
1. Baseline Retinopathy Vs Retinopathy at the end BE 
 
Baseline Retinopathy/ 
Retinopathy at the end 
MODERATE 
NPDR 
SEVERE 
NPDR 
VERY SEVERE 
NPDR 
  PDR Total 
MODERATE NPDR 11(73%) 4(27%) 0 0 15 
SEVERE NPDR 0 9(53%) 8(47%) 0 17 
VERY SEVERE NPDR 0 0 8(44%) 10(56%) 18 
Total 11 13 16 10 50 
 
    About 73% of patients diagnosed as Moderate NPDR in BE at Baseline 
remained the same at the end while the remaining 27% progressed to severe 
NPDR. Among patients who were diagnosed to have severe NPDR at baseline, 
47% progressed to very severe stage and the remaining 53% remained in the 
severe NPDR stage. Around 56% of patients who had Very severe NPDR at the 
beginning of the study progressed to Proliferative diabetic retinopathy and 44% 
had very severe NPDR.  
 
Progression/ 
Baseline Retinopathy 
NO Progression Progression 
Present 
Grand 
Total 
MODERATE NPDR 11(73%) 4(27%) 15 
SEVERE NPDR 9(53%) 8(47%) 17 
VERY SEVERE 
NPDR 
8(44%) 10(56%) 18 
Grand Total 28 22 50 
 
 
 
72 
 
 
 
 
2. Oscillatory potentials Vs Retinopathy at the end BE 
 
Oscillatory potentials/ 
Retinopathy at the End 
BE 
MODERATE 
NPDR 
SEVERE 
NPDR 
VERY SEVERE 
NPDR 
  PDR Total 
OP ABNORMAL 1(5%) 5(23%) 6(27%) 10(45%) 22 
OP NORMAL 10(36%) 8(28%) 10(36%) 0 28 
Total 11 13 16 10 50 
 
          Around 45 % of the patients with abnormal oscillatory potentials were 
diagnosed to have proliferative diabetic retinopathy, another 23 % had severe 
NPDR and 27 % had very severe NPDR. Among patients with normal OP, 36% 
had moderate NPDR, 28% had severe NPDR, 36 % had very severe NPDR and 
none had PDR.  
Oscillatory potentials Vs Progression of DR 
 
 
OPs/ PROGRESSION 
OF DR 
PROGRSSED NO 
PROGRESSION 
Total 
OP NORMAL 5(18%) 23(82%) 28 
OP ABNORMAL 17(77%) 5(23%) 22 
 Total 22 28 50 
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In this study, around 82% of patients with normal OP did not 
progress whereas 18% of patients showed progression. About 77% of 
patients with abnormal OP progressed to next level of diabetic 
retinopathy while 23% did not progress. p value determined by two 
tailed chi square test was found to be 0.0001 which was extremely 
statistically significant. 
              
 
 
 
 
 
3. FASTING BLOOD SUGAR Vs PROGRESSION OF DR 
 
FBS / PROGRESSION OF 
DR 
PROGRESSION
PRESENT 
NO 
PROGRESSION 
TOTAL 
<126 mg/dl 12(31%) 27(69%) 39 
≥126 mg/dl 10(91%) 1(9%) 11 
TOTAL 22 28 50 
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           In this study, 31% of patients with fasting blood sugar <126 mg/dl 
progressed to next stage of diabetic retinopathy whereas 69% of patients with 
fasting blood sugar <126 mg/dl did not progress. Around 91% of patients with 
FBS ≥126 mg/dl showed progression of diabetic retinopathy while the remaining 
9% did not show progression. The mean FBS in patients with and without 
progression were 120.55 ± 20.48 mg/dl and 106.29 ± 14.53 mg/dl respectively. p 
value determined by two tailed chi-square test was found to be 0.0014 which was 
< 0.05, hence statistically significant. 
 
 
 
 
4. Systolic Blood Pressure Vs Progression Of DR 
 
SYSTOLIC BP/ 
PROGRESSION OF DR 
PROGRESSED NO 
PROGRESSION 
TOTAL 
<140 9(28%) 23(72%) 32 
≥140 13(72%) 5(28%) 18 
TOTAL 22 28 50 
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In this study, 72 % of the patients with systolic BP <140 did not progress 
whereas 28% progressed. Around 28% of patients with systolic BP ≥140 did not 
progress while 72% of patients showed progression. The mean systolic BP in 
those who progressed and who did not progress were 135 ± 8/02 and 125.36 ± 
14.27 mm of Hg respectively. p value determined by the two tiled chi-square test  
was 0.0026 which was <0.05 meaning that it was statistically significant.     
                               
 
 
 
5. DIASTOLIC BP Vs PROGRESSION OF DR 
 
DIASTOLIC BP/ 
PROGRESSION OF DR 
PROGRESSED NO PROGRESSION TOTAL 
<90 13(38%) 21(62%) 34 
≥90 9(56%) 7(44%) 16 
TOTAL 22 28 50 
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In this study, 62% of patients with diastolic BP <90 did not show 
progression whereas 38% progressed. About 56% of the patients with diastolic 
BP progressed to next stage of retinopathy while 44% of the patients did not 
progress. The mean diastolic BP in patients who showed progression was 86.36 
± 6.58 mm of Hg and that in patients who did not progress was 81.07 ± 7.37 mm. 
p value was found to be 0.2313 which was > 0.05 meaning statistically not 
significant.         
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DISCUSSION 
  
 Diabetic retinopathy is one of the potentially blinding condition in middle 
age and elderly patients. Among the various factors that can influence the 
progression of diabetic retinopathy, the impact of fasting blood sugar levels, 
blood pressure and ERG- Oscillatory Potentials are discussed in this study. 
 In this study, most common (34 %) age group presented was 56 to 60 years 
followed by 60 to 65 years (16 %). The least common age group presented was 
36 to 40 years (2 %). This may be due to the fact that most of the type II diabetic 
patients are asymptomatic until 40 years and it is consistent with similar kind of 
studies (16, 17, 18 19).  The oldest patient was 69 years old and youngest patient 
was 39 years old. The mean age at presentation was 57.22 ±7.86 years. Out of 50 
patients participated in the study, 26 were females and 22 were males.  
 In this study, 30% of the patients had moderate non proliferative diabetic 
retinopathy, 34 % had severe non proliferative diabetic retinopathy and the 
remaining 36 % had very severe NPDR at baseline. 
 In this study, maximum number of patients in all the three baseline 
retinopathy groups belonged to 56 to 60 years age group. This is due to the fact 
that overall more number of patients come under this age group. The mean age at 
presentation of patients with moderare diabetic retinopathy was 55.01 ± 7.54 
years. The mean age at presentation in severe retinopathy and very severe 
retinopathy groups were 58 ± 8.27 years and 58.28 ± 7.81 years respectively. 
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 Around 38% of the patients had diabetes for a period of 6-10 years in this 
study which was the most common duration category encountered. The next 
common duration period was 0-5 years (36 %). Only 2 % had diabetes for a period 
more than 20 years. 
 In this study, about 80 % of the patients with moderate NPDR had diabetes 
for a period less than 5 years and remaining 20 % had 6-10 years of diabetes. 
Most common Duration of diabetes in patients with severe NPDR was 6-10 years 
(52.91%) followed by 0-5 years (23.52%). Patients with very severe NPDR had 
diabetes for 6-10 years most commonly (39 %) followed by 11-15 years (33 %). 
WESDR Study states that the prevalence of diabetic retinopathy varied from 
28.8% in persons with diabetes for less than five years to 77.8% in persons who 
had diabetes for 15 or more years. The rate of proliferative diabetic retinopathy 
varied from 2.0% in persons who had diabetes for less than five years to 15.5% 
in persons who had diabetes for 15 or more years (8, 23). 
 In this study, most of the patients (72%) were treated with oral 
hypoglycemic agents for diabetes. Around 24 % of the patients were treated with 
oral hypoglycemic agents and insulin injections. Only 4 % of the patients were 
not under any treatment for diabetes. After UKPDS, most of the patients with 
type II DM are treated with one or more oral hypoglycemic agents (7). 
    Around 87% of the patients with moderate NPDR, 82 % of the severe NPDR 
group and 50 % of the very severe NPDR group in this study were under treatment 
with oral hypoglycemic agents alone, whereas 45 % of the very severe NPDR 
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group, 18 % of the severe NPDR group and 6 % of the moderate NPDR group 
were treated with a combination of oral hypoglycemic agents and insulin 
injection. 6% of moderate NPDR group and 5 % of very severe NPDR group 
were not under treatment. 
 In this study, Hypertension was the most common systemic comorbidity 
found in 48 % of the patients. Around 24 % of the patients had no systemic illness, 
14 % had nephropathy, 12 % had coronary artery disease and 2 % had stroke. The 
increased risk of proliferative retinopathy was associated with the presence of 
hypertension at baseline (8). 47 % of patients in moderate NPDR, 53 % of severe 
group and 44 % of very severe NPDR group were hypertensive. Around 12 % of 
severe group and 28 % of very severe NPDR group had nephropathy at baseline. 
18 % of severe group and 17 % of very severe NPDR group had coronary artery 
disease. 1 patient in moderate NPDR group had a previous attack of stroke.  
In this study, 48 % of the patients had their fasting blood sugar level 
between 100 and 119 mg/dl followed by 24 % each in <100 mg/dl and 120-149 
mg/dl groups and 4 % in the 150-200 range. The mean Fasting blood sugar in the 
study was 112.56 ± 18.63 mg/Dl. The levels of fasting blood glucose were highest 
in patients with early PDR progressively decreased, being lowest in patients with 
moderate NPDR, findings that were supported by the DCCT study and the study 
by Kroc Collaborative Study Group (13, 29). 
About 60% of the patients in this study with moderate NPDR had fasting 
blood sugar in the range of 100-119 mg/Dl and the remaining 40% had FBS < 
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100 mg/dl. In the severe NPDR group, 59% of the patients’ FBS was between 
100-119 mg/dl, 35 % had FBS in the range of 120-149 mg/dl and 6 % had <100 
mg/dl. 33 % of patients with very severe NPDR had their fasting blood sugar 
levels between 120-149 mg/dl whereas 28 % fall in the group of 100-119 mg/dl, 
another 28 % in <100 mg/dl and about 11 % had FBS in the range of 150-200 
mg/dl. The average fasting blood sugar in the moderate NPDR, severe NPDR and 
very severe NPDR were 102.47 ± 7.79 mg/dl, 113.35 ± 12.74 mg/dl and 120.22 
± 25.40 mg/dl respectively. 
          In this study, 46 % of the patients had their systolic blood pressure in the 
range of 120-139 mm of Hg, 36 % of the patients had their systolic BP in the 
range of 140-159 mm of Hg, 16% had their systolic BP <120 mm of Hg and the 
remaining 2 % had BP ≥ 160 mm of Hg. The mean systolic BP was 129.60 ± 
12.77 mm of Hg. The UKPDS showed that the incidence of retinopathy was 
associated with systolic blood pressure (12). 
The mean systolic blood pressure in moderate, severe and very severe 
NPDR were 120.67 ± 11.63, 134.12 ± 12.78, 132.78 ± 10.18 mm of Hg 
respectively. About 53 % of the patients with moderate NPDR had their systolic 
BP in the range of 120-139 mm of Hg, 40 % of the patients fell in the <120 mm 
of Hg group and remaining 7% had 140-159 mm of Hg.. In the severe NPDR 
group, 41% of the patients had systolic BP in the range of 120-139 mm of Hg, 47 
% of the patients’ systolic BP was in the range of 140-159 mm of Hg, 6% in <120 
mm of Hg group and the remaining 6 % in ≥160 mm of Hg group. In very severe 
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NPDR category, 50% of the patients fell in the 140-159 mm of Hg group, 44 % 
had their systolic BP in the range of 120-139 mm of Hg and 6 % fell in <120 mm 
of Hg group.  
In this study, around 46% of the patients had diastolic BP in the range of  
80-89 mm of Hg followed by 28% in 90-99 mm of Hg, 22 % in <80 mm of Hg 
and 4 % in  ≥ 100 mm of Hg. The mean diastolic BP was 82.6 ± 8.53 mm of Hg.   
The mean diastolic blood pressure in moderate, severe and very severe 
NPDR was 80 ± 6.55 mm of Hg, 85.29 ± 7.99 mm of Hg and 84.44 ± 7.05 mm 
of Hg respectively. In the moderate NPDR group, 60 % of the patients had 
diastolic BP in the range of 80-89 mm of Hg, 27 % of the patients’ diastolic BP 
was < 80 mm of Hg and 13 % in the range of 90-99 mm of Hg group. About 36 
% of the patients with severe NPDR had their diastolic BP in the range of 90-99 
mm of Hg, 29 % of the patients fell in the <80 mm of Hg group, another 29 % of 
patients fell in the 80-89 mm of Hg and the remaining 6 % had their diastolic BP 
> 100 mm of Hg. In very severe NPDR category, 50% of the patients fell in the 
80-89 mm of Hg group, 33 % had their systolic BP in the range of 90-99 mm of 
Hg, 11 % fell in <80 mm of Hg group and remaining 6 % had diastolic BP >100 
mm of Hg. 
In the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), 
diastolic blood pressure was a significant predictor of progression of diabetic 
retinopathy to proliferative diabetic retinopathy over 14 years of follow up in 
patients with younger onset (type 1) diabetes mellitus, independent of 
82 
 
glycosylated haemoglobin and the presence of gross proteinuria. However, 
neither systolic or diastolic blood pressure nor hypertension at baseline were 
associated with the incidence and progression of retinopathy in people with type 
2 diabetes mellitus 
            The mean baseline visual acuity in RE and LE were 0.51 (~6/18) and 0.48 
± 0.31 (6/18) log MAR units respectively. Around 52 % of the patients each in 
RE and LE presented with a baseline visual acuity in the range of 6/6 – 6/18 (0-
0.48) followed by 44 % of patients in RE and 48% in LE in the range of <6/18 – 
6/60 (>0.48-1) and the remaining 4 % in RE fell in the group of <6/60-3/60(>1-
1.30). 
            In this study, about 58% of the patients presented with clinically 
significant macular edema in RE and 60 % of the patients presented with CSME 
in LE. 
In this study, around 44 % of patients had abnormal oscillatory potentials 
in BE and 56 % of patients had normal oscillatory potentials in BE. Around 73% 
of the patients with moderate NPDR in BE had normal oscillatory potentials 
while 27% had abnormal OPs. In severe NPDR group, 59 % had normal OPs and 
41 % had abnormal OPs whereas 61% of very severe NPDR patients had 
abnormal OPs and 39 % had normal OPs. 
The study shows that 24 % of patients had delayed b wave implicit time in 
BE and remaining patients did not have any other findings. In this study, all 
patients with moderate NPDR in BE had normal ERG. About 24% of patients 
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with severe NPDR and 44% of patients with very severe NPDR had delayed b 
wave implicit times. The remaining patients in the two groups had normal ERG. 
In “Photopic electroretinogram implicit time in diabetic retinopathy” study, the 
implicit time was significantly delayed in eyes with moderate NPDR, PPDR and 
PDR relative to eyes with mild NPDR, eyes without retinopathy or normal eyes. 
The delay of implicit time significantly increased as the severity of retinopathy 
progressed from mild NPDR to PPDR (34, 42). 
Around 18 % of patients received grid laser with anti-VEGF injections for 
CSME in RE and 20% received the same treatment in LE. 40 % of the patients 
received grid laser as treatment each in RE and LE 
 In this study, around 32% of the patients were diagnosed to have Very 
severe NPDR followed by 26% had severe NPDR, 22% had moderate NPDR and 
20% were diagnosed to have proliferative diabetic retinopathy at the end of the 
study. 
 The study shows that about 58 % and 60% of patients had their CSME 
treated at the end of the study in RE and LE respectively. 28 % of patients each 
had normal macula at the end in BE. 14 % of patients had CSME in RE and 12% 
of patients were found to have CSME in LE. 
 In this study, 70 % and 76 % of patients had BCVA at the end in the range 
of 6/6-6/18 in RE and LE respectively. About 30 % of patients in RE and 24% of 
patients in LE had final BCVA of <6/18-6/60. 
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 Around 56% of the patients participated in the study did not progress to 
next stage of diabetic retinopathy. The remaining 44% progressed to next level 
of diabetic retinopathy. 
About 73% of patients diagnosed as Moderate NPDR in BE at Baseline 
remained the same at the end while the remaining 27% progressed to severe 
NPDR. Among patients who were diagnosed to have severe NPDR at baseline, 
47% progressed to very severe stage and the remaining 53% remained in the 
severe NPDR stage. Around 56% of patients who had Very severe NPDR at the 
beginning of the study progressed to Proliferative diabetic retinopathy and 44% 
had very severe NPDR. Another study shows that people with type 2 diabetes 
without retinopathy at the time of their first retinal examination were at low risk 
of progressing to proliferative retinopathy and at very low risk of progressing to 
either PDR or maculopathy even after 5 years of follow-up. In contrast, patients 
with non-proliferative or proliferative retinopathy at their first retinal examination 
were at much higher risk of progression (15, 16, 17, 22). 
Around 45% of the patients with abnormal oscillatory potentials were 
diagnosed to have proliferative diabetic retinopathy, another 23 % had severe 
NPDR and 27 % had very severe NPDR. Among patients with normal OP, 36% 
had moderate NPDR, 28% had severe NPDR, 36 % had very severe NPDR and 
none had PDR. 
               In this study, around 82% of patients with normal OP did not progress 
whereas 18% of patients showed progression. About 77% of patients with 
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abnormal OP progressed to next level of diabetic retinopathy while 23% did not 
progress. p value determined by two tailed chi square test was found to be 0.0001 
which was extremely statistically significant. Bresnick GH et al stated in their 
study that those eyes with abnormal OP amplitudes at study entry had a tenfold 
higher rate of progression to DRS-HRC than did eyes with normal amplitudes 
(33). 
           In this study, 31% of patients with fasting blood sugar <126 mg/dl 
progressed to next stage of diabetic retinopathy whereas 69% of patients with 
fasting blood sugar <126 mg/dl did not progress. Around 91% of patients with 
FBS ≥126 mg/dl showed progression of diabetic retinopathy while the remaining 
9% did not show progression. The mean FBS in patients with and without 
progression were 120.55 ± 20.48 mg/dl and 106.29 ± 14.53 mg/dl respectively. p 
value determined by two tailed chi-square test was found to be 0.0014 which was 
< 0.05, hence statistically significant. The mean fasting glucose level was higher 
in those whose retinopathy progressed than in those without progression as shown 
by numerous studies (8, 13, 15, 18, 24, 25, 29). 
 In this study, 72% of the patients with systolic BP <140 did not 
progress whereas 28% of the patients progressed. Around 28% of patients with 
systolic BP ≥140 did not progress while 72% of patients showed progression. The 
mean systolic BP in those who progressed and who did not progress were 135 ± 
8/02 and 125.36 ± 14.27 mm of Hg respectively. p value determined by the two 
tiled chi-square test  was 0.0026 which was <0.05 meaning that it was statistically 
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significant. In “Glycemic Exposure and Blood Pressure Influencing Progression 
and Remission of Diabetic Retinopathy study”, SBP was also a significant risk 
factor for progression to mild BDR from the initial retinopathy-free state and the 
reduction in SBP by 1 SD (17.28 mmHg) was associated with a 20% increased 
chance of regression back to the retinopathy-free state (29). 
The study shows that 62% of patients with diastolic BP <90 did not show 
progression whereas 38% progressed. About 56% of the patients with diastolic 
BP progressed to next stage of retinopathy while 44% of the patients did not 
progress. The mean diastolic BP in patients who showed progression was 86.36 
± 6.58 mm of Hg and that in patients who did not progress was 81.07 ± 7.37 mm. 
p value was found to be 0.2313 which was > 0.05 meaning statistically not 
significant. 
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SUMMARY 
 
 
Around 50 patients with type 2 diabetes mellitus and non-proliferative 
diabetic retinopathy were included in this prospective, observational study which 
was carried out at the department of vitreo-retina services, Regional Institute of 
ophthalmology and Government ophthalmic hospital, Madras Medical College, 
Chennai, over a period of 12 months. 
The aim was to analyze the factors like ERG oscillatory potentials, fasting 
blood sugar and blood pressure in predicting progression of diabetic retinopathy. 
50 patients were enrolled in the study based on the selection criteria, baseline 
parameters documented and followed up to look for progression of diabetic 
retinopathy. 
 In this study, most common (34 %) age group presented was 56 to 60 years 
26 patients were females and 22 were males. 30% of the patients had moderate 
NPDR, 34 % had severe NPDR and the remaining 36 % had very severe NPDR. 
 The mean fasting blood sugar in the moderate NPDR, severe NPDR 
and very severe NPDR were 102.47 ± 7.79 mg/dL, 113.35 ± 12.74 mg/dL  and 
120.22 ± 25.40 mg/dL respectively.  
The mean systolic blood pressure in moderate, severe and very severe 
NPDR were 120.67 ± 11.63, 134.12 ± 12.78, 132.78 ± 10.18 mm of Hg 
respectively. The mean diastolic blood pressure in moderate, severe and very 
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severe NPDR was 80 ± 6.55 mm of Hg, 85.29 ± 7.99 mm of Hg and 84.44 ± 7.05 
mm of Hg respectively. 
The mean baseline visual acuity in RE and LE were 0.51 (~6/18) and 0.48 
± 0.31 (6/18) log MAR units. In this study, about 58% of the patients presented 
with clinically significant macular edema in RE and 60 % of the patients 
presented with CSME in LE.  
In this study, 73% of the patients with moderate NPDR in BE had normal 
oscillatory potentials while 27% had abnormal OPs. In severe NPDR group, 59 
% had normal OPs and 41 % had abnormal OPs whereas 61% of very severe 
NPDR patients had abnormal OPs and 39 % had normal OPs. In this study, 24 % 
of patients had delayed b wave implicit time in BE and remaining patients did not 
have any other findings. 
At the end of the study, around 32% of the patients were diagnosed to have 
Very severe NPDR followed by 26% had severe NPDR, 22% had moderate 
NPDR and 20% were diagnosed to have proliferative diabetic retinopathy.  
About 73% of patients diagnosed as Moderate NPDR in BE at Baseline 
remained the same at the end while the remaining 27% progressed to severe 
NPDR. Around 47% of patients with severe NPDR progressed to very severe 
stage and the remaining 53% remained in the severe NPDR stage. Around 56% 
of patients who had Very severe NPDR at the beginning of the study progressed 
to Proliferative diabetic retinopathy and 44% had very severe NPDR. 
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               In this study, around 82% of patients with normal OP did not progress 
whereas 18% of patients showed progression. About 77% of patients with 
abnormal OP progressed to next level of diabetic retinopathy while 23% did not 
progress. p value determined by two tailed chi square test was found to be 0.0001 
which was extremely statistically significant. OP amplitude also has been shown 
to predict the continued progression of diabetic retinopathy (33, 42).  
           In this study, 31% of patients with fasting blood sugar <126 mg/dl 
progressed to next stage of diabetic retinopathy whereas 69% of patients with 
fasting blood sugar <126 mg/dl did not progress. Around 91% of patients with 
FBS ≥126 mg/dl showed progression of diabetic retinopathy while the remaining 
9% did not show progression. p value was found to be 0.0014 which was < 0.05, 
hence statistically significant. 
In this study, 72 % of the patients with systolic BP <140 did not progress 
whereas 28% of the patients progressed. Around 28% of patients with systolic BP 
≥140 did not progress while 72% of patients showed progression. p value 
determined was 0.0026 which was <0.05 meaning that it was statistically 
significant. 
 In this study, 62% of patients with diastolic BP <90 did not show 
progression whereas 38% progressed. About 56% of the patients with diastolic 
BP ≥ 90 progressed to next stage of retinopathy while 44% of the patients did not 
progress. p value was found to be 0.2313 which was > 0.05 meaning statistically 
not significant. 
90 
 
 
LIMITATIONS OF THE STUDY 
 
 
Limitations of our study were the small sample size and 
short follow up period of 12 months. Larger study group and 
longer follow up are necessary to substantiate that all these 
factors predict progression of diabetic retinopathy.  
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CONCLUSION 
To conclude, this study has demonstrated that factors like oscillatory 
potentials, fasting blood sugar and systolic blood pressure can predict the 
progression of diabetic retinopathy. With this, patients who are at greater risk for 
progression can be followed up closely and treated effectively.  
Whenever an electroretinogram set up is available, it is preferable to get a 
ERG done for all patients with non-proliferative diabetic retinopathy as 
Oscillatory potentials antedates proliferation by months- years. It is because of its 
ability to detect inner retinal ischemia earlier which is the driving force of 
proliferative diabetic retinopathy. 
Patients with high fasting and post prandial blood sugars should be brought 
under good control of glycemic status. Patients having systemic comorbidities 
like hypertension, hypercholesterolemia are at high risk for progression and hence 
these patients should be followed up at frequent intervals and should be instituted 
appropriate treatment.  
By all these measures, the burden of blindness caused by diabetic 
retinopathy could be reduced especially in the economically active population. 
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THESIS PROFORMA 
NAME:  
IP / OP No (FF No): 
AGE / SEX: 
CONTACT NUMBER:                                            
ADDRESS: 
 
 
TYPE OF DIABETES & DURATION OF DIABETES: 
TREATMENT HISTORY: 
 
RECENT GLYCEMIC STATUS (FBS & PPBS): 
BLOOD PRESSURE: 
PAST H/O - OCULAR TREATMENT: 
 
OTHER SYSTEMIC ILLNESS, DURATION & TREATMENT:  
(HT/CAD/ HYPERLIPIDEMIA/OTHERS) 
 
VISUAL COMPLIANTS: 
 
VISIT: 1 
VISIT 1  
VISIT 2  
VISIT 3  
VISIT 4  
VISIT 5  
VISIT 6  
PHOTO 
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RE  LE 
 BCVA  
 TENSION  
 ANTERIOR SEGMENT  
 FUNDUS  
 
DIAGNOSIS: 
ELECTRO RETINOGRAM: 
VISIT NO.2 
Recent glycaemic status & Blood Pressure: 
 
Any specific complaints: 
 
Visit no. 3: 
Recent glycaemic status & Blood Pressure: 
Any specific complaints: 
 
RE  LE 
 BCVA  
 TENSION  
 ANTERIOR SEGMENT  
 FUNDUS  
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RE  LE 
 BCVA  
 TENSION  
 ANTERIOR SEGMENT  
 FUNDUS  
 
Visit no. 4 : 
Recent glycaemic status & Blood Pressure: 
Any specific complaints: 
 
RE  LE 
 BCVA  
 TENSION  
 ANTERIOR SEGMENT  
 FUNDUS  
 
Summary: 
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KEY TO MASTER CHART 
1. S. No.: Serial number  
2. Sex: M– Male; F – Female  
3. Hospital ID 
4. Duration of diabetes mellitus 
5. Treatment for DM-Rx: Insulin – I, Oral Hypoglycaemic agents – O, Both 
Insulin and Oral hypoglycaemic agents – IO. 
6. Systemic comorbidities – SYS: Hypertension - H, Coronary Artery Disease 
– C, Stroke- S, Nephropathy (Renal) – R, N-None. 
7. Fasting Blood Sugar -  FBS 
8. Systolic Blood Pressure – SBP 
9. Diastolic Blood Pressure – DBP 
10. Best Corrected Visual acuity RE – VA RE 
11. Best Corrected Visual acuity LE – VA LE 
12. Intraocular pressure RE – IOP RE 
13. Intraocular pressure LE – IOP LE 
14. Baseline Retinopathy BE (BL-R): M - Moderate NPDR, S - Severe NPDR, 
VS - Very severe NPDR. 
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15. Macula RE (Mac RE): C- CSME, N- Normal. 
16. Macula LE (Mac LE): C- CSME, N- Normal. 
17. Oscillatory Potentials – OPs; N- Normal, A – Abnormal. 
18. Other ERG abnormalities (ERG): D – delayed b wave implicit time, N -  
normal 
19. Treatment of maculopathy (Rx ME): G- Grid, AV – anti- VEGF, AV + G- 
anti-VEGF and grid 
20. BCVA RE at the end of the study RE – VA RE- E 
21. BCVA LE at the end of the study LE- VA LE - E 
22. Retinopathy at the end of the study BE: M - Moderate NPDR, S - Severe 
NPDR, VS - Very severe NPDR, P – PDR. 
23. Maculopathy at the end of the study RE (Mac RE end): C- CSME, N- 
Normal, T- treated CSME. 
24. Maculopathy at the end of the study LE (Mac LE end): C- CSME, N- 
Normal, T- treated CSME. 
25. Progression of Diabetic retinopathy BE: Yes, No.  
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